http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-084194-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_252c7817c4e8e28516757ae3b471b00d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64 |
| filingDate | 2011-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_031366fac602340ac9b2e85425987301 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_542fc56854a0ce5b3bcbdd83c0446bed |
| publicationDate | 2013-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-084194-A1 |
| titleOfInvention | ARILSULFONAMIDE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF SPECIFIC OPHTHALMOLOGICAL DISORDERS |
| abstract | Pharmaceutical composition: Claim 1: Compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein: R1 represents an aromatic ring that is unsubstituted or substituted with one or more atoms or groups of atoms chosen from the halogens, C1-3 alkyl groups, C1-3 alkoxy groups, nitro, cyano, trifluoromethyl or trifluoromethoxy groups; R2 represents a hydrogen atom, or a cyclic, linear or branched hydrocarbon chain having 1 to 4 carbon atoms optionally substituted with a phenyl group, with a CONH2 group or with one or more fluorine atoms; R3 represents a hydrogen atom, a hydroxy group, or forms with R4 a group -CH = N- or a linear or branched C2-4 alkylene group; R4 represents a hydrogen atom or forms with R3 a group -CH = N- or a linear or branched C2-4 alkylene group; R5 represents a hydrogen atom or a C1-3 alkyl group; R6 represents a hydrogen atom or a halogen; Y represents a C2-4 alkylene group, saturated or unsaturated, linear or branched, optionally interrupted between two carbon atoms by an oxygen atom; for the prevention, treatment and / or reduction of macular edema. Claim 3: Compound according to claim 1 or claim 2, characterized in that the compound is the compound of formula (2) or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2010-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.